Advertisement

20131203_10

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
ISSUE 43 – NOV. 15, 2013PDF

example

“Master Protocol” To Rely on Biomarkers In Testing Multiple Lung Cancer Agents
Advertisement

A new kind of clinical trial that will assign patients to therapy based on molecular characteristics of their disease is being launched by a coalition of government agencies, pharmaceutical companies, and a non-government organization.

The effort, called the lung cancer “Master Protocol,” is a phase II and phase III trial that would test five drugs, assigning patients to therapy based on tumor biomarkers.

photoVarmus: “We Are Shrinking Everything” To Keep Grant Numbers Level During Cuts

As NCI digs out after the two-week shutdown of the federal government, its leadership has to contend with the prospect of another shutdown weeks away, which may kick in after the current continuing resolution expires Jan. 15, 2014.

photoFDA Grants Accelerated Approval to Imbruvica

FDA granted an accelerated approval to Imbruvica (ibrutinib) for mantle cell lymphoma patients who have received at least one prior therapy.

Imbruvica was approved four months after submission of its New Drug Application. The agent is sponsored by Pharmacyclics Inc.

Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement